Immunoconjugates Against Solid Tumors: Mind the Gap

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer

(2009) E. A. Perez et al.   ANNALS OF ONCOLOGY

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

(2009) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

(2009) M. M. Schmidt et al.   MOLECULAR CANCER THERAPEUTICS

Development trends for therapeutic antibody fragments

(2009) Aaron L Nelson et al.   NATURE BIOTECHNOLOGY

A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo

(2008) D. Jackson et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker

(2008) E. Oflazoglu et al.   CLINICAL CANCER RESEARCH

High Shed Antigen Levels within Tumors: An Additional Barrier to Immunoconjugate Therapy

(2008) Y. Zhang et al.   CLINICAL CANCER RESEARCH

Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer

(2008) Matthew D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CD30 diabody-drug conjugates with potent antitumor activity

(2008) K. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS